ライフサイエンスコーパス: nociceptin

1 Oddi (SO) were immunostained for orphanin FQ/nociceptin.

2 ted peptide (cgrp), galanin, hypocretin, and nociceptin.

3 eased, indicating an enhanced sensitivity to nociceptin.

4 induced increases in calcium was mimicked by nociceptin (0.1 microM).

5 Microinjections (30 nl) of nociceptin (0.15-0.62 mM) into the nCom elicited depress

6 eptors, into the nCom blocked the effects of nociceptin (0.31 mM, the maximally effective concentrati

7 Microinjections of nociceptin (0.31, 0.62, 1.25 and 2.25 mmol/L) into the n

8 a-receptors were labelled with [(3)H] leucyl-nociceptin (0.4 nM), [(3)H] DAMGO (4 nM), [(3)H] deltorp

9 e nociceptin antagonist [Phe1Psi(CH2NH)Gly2]-nociceptin(1-13) NH2 (NCA), a peptide that on its own ex

10 pseudopeptide, [Phe(1)iota(CH(2)-NH)Gly(2)]-nociceptin(1-13)-NH(2) (hereafter: [FG]N/OFQ(1-13)NH(2))

11 The NOP antagonist [Nphe1]-nociceptin(1-13)NH2 increased the IPSP amplitudes in res

12 Application of [Nphe1]Nociceptin(1-13)NH2, a nociceptin receptor (NOP) antagon

13 L1 receptor antagonist, [Phe1Psi(CH2-NH)Gly2]Nociceptin(1-13)NH2.

14 Prior microinjections of [N-Phe(1)]-nociceptin-(1-13)-NH(2) (4.5 mM), a specific antagonist

15 blockade of nociceptin effects by [N-Phe(1)]-nociceptin-(1-13)-NH(2) and endomorphin-2 by naloxone, w

16 Nociceptin (100 nM-1 microM) potently inhibited the spon

17 We found that nociceptin (100-1000 nM) diminished basal-evoked compoun

18 Nociceptin (3 mg/kg, intraperitoneal) effectively inhibi

19 Nociceptin, a 17 amino acid opioid-like peptide that has

20 ough estrogen and progesterone regulation of nociceptin activity.

21 Also, the increased effectiveness of nociceptin after axotomy supports the hypothesis that it

22 hyl]-N,N -diethylbenzamide (SNC80)] or NOPR (nociceptin) agonists to inhibit forskolin-stimulated ade

23 Nociceptin also blocked the ethanol-induced augmentation

24 Nociceptin also prevented the ethanol-induced augmentati

25 Immunoreactivity for nociceptin, an endogenous ligand for the ORL1 opioid rec

26 eceptors also potentiated spinal orphanin FQ/nociceptin analgesia.

27 paration, we investigated the interaction of nociceptin and CRF on evoked and spontaneous GABAergic t

28 new evidence for an interaction between the nociceptin and CRF systems in the CeA.

29 Co-application of nociceptin and DADLE to neurons that were responsive to

30 To develop tools to study the function of nociceptin and NOP receptor, our research effort sought

31 Here, we identify the neuropeptides nociceptin and somatostatin, a neurotransmitter and neur

32 ( approximately 70%) were inhibited by both nociceptin and the delta-opioid receptor agonist, [D-ala

33 butions of orphanin FQ (OFQ/N; also known as nociceptin) and its cognate receptor, opioid receptor-li

34 matostatin controls ectodermal expression of nociceptin, and both peptides regulate Pax6 in lens and

35 Agonists for mu-opioid, nociceptin, and GABA(B) receptors induced postsynaptic c

36 The OFQ-activated current was blocked by the nociceptin antagonist [Phe1Psi(CH2NH)Gly2]-nociceptin(1-

37 Nociceptin appears to regulate a host of physiological f

38 start points for the transcription of prepro-nociceptin are identified by an 'oligoribonucleotide-cap

39 The present results identify nociceptin as a potent chemoattractant and provide a nov

40 ypothalamic membranes, utilizing [125I]Tyr12-nociceptin as ligand.

41 eous locomotor activity, whereas galanin and nociceptin attenuated these behaviors.

42 approximately 50% decrease in [(3)H] leucyl-nociceptin binding was seen in heterozygous ORL1 mutant

43 Notably, nociceptin blocked the inhibition induced by acute ethan

44 cause the ORL-1 receptor agonist orphanin FQ/nociceptin blocks opioid-induced antinociception, we tes

45 ions of morphine and the opioid-like peptide nociceptin (both 1 mu) on dorsal root ganglion (DRG) neu

46 Nociceptin bound with picomolar affinity, dynorphin A wi

47 selectively responsive either to DADLE or to nociceptin, but not both.

48 In alert rats, i.c.v. injection of nociceptin caused a significant decrease in the gain of

49 The NOPR agonist, nociceptin, caused robust NOPR-YFP receptor internalizat

50 In neurons from ethanol-dependent animals, nociceptin decreased basal GABAergic transmission and bl

51 ma-aminobutyric acid (GABA) release, whereas nociceptin diminishes it.

52 In neurons from naive animals, nociceptin dose-dependently diminished basal-evoked GABA

53 The blockade of nociceptin effects by [N-Phe(1)]-nociceptin-(1-13)-NH(2)

54 When injected in murine air pouches, nociceptin elicited leukocyte infiltration in a concentr

55 Following highest i.t. dose of nociceptin employed (20 nmol), the gestational or sex st

56 Nociceptin evoked PMN chemotaxis with maximal activity a

57 Nociceptin exerts its antistress effect by counteracting

58 Unlike mice, orphanin FQ/nociceptin fails to elicit hyperalgesia in the rat follo

59 es to the exclusion of mammalian orphanin FQ/nociceptin from classic opioid ligands (i.e. F1Y and L14

60 , and specific binding with [(125)I]-labeled nociceptin gave an apparent K(d) approximately 1.5 nM fo

61 or the regulatory mechanisms of human prepro-nociceptin gene expression.

62 stream regulatory region of the human prepro-nociceptin gene has been cloned from adaptor-ligated gen

63 Our data suggest that nociceptin has a role in regulating the GABAergic system

64 ore the importance of the hormonal milieu to nociceptin hypoalgesic sensitivity.

65 e investigated the NMR solution structure of nociceptin in membrane-like environments (trifluoroethan

66 d calcium flux, alanine-scanning variants of nociceptin indicated that functionally important residue

67 Furthermore, hypocretin and nociceptin induced modality-specific differences in resp

68 The antagonist also blocked nociceptin-induced decreases in glutamatergic responses,

69 thanol-treated (ethanol-dependent) rats, the nociceptin-induced inhibition of evoked EPSP amplitude w

70 cute ethanol (44 mM) and ethanol blocked the nociceptin-induced inhibition of evoked EPSPs in CeA neu

71 ingly, in CeA of ethanol-dependent rats, the nociceptin-induced inhibition of IPSCs was increased, in

72 e 362, serine 363, and threonine 365 blocked nociceptin-induced internalization of NOPR.

73 We also found that nociceptin-induced NOPR-mediated JNK but not ERK signali

74 and the ORL-1 receptor agonist, orphanin FQ/nociceptin, induces analgesia at the spinal level, but a

75 ives of this study were to determine whether nociceptin inhibits acid-evoked cough in conscious anima

76 sent in neural tissues and its activation by nociceptin is involved in the processing of pain signals

77 This hypoalgesic effect of nociceptin is not limited to attenuating the gestational

78 n rats, intrathecal (i.t.) administration of nociceptin is without effect on basal thresholds for res

79 channel current in axotomized DRG neurons by nociceptin led to a reduction in Ca2+-dependent K+ condu

80 dings demonstrate that endogenously released nociceptin may have a hitherto unexplored role in the fu

81 Thus, nociceptin may represent a therapeutic target for allevi

82 These properties of nociceptin may underlie its anti-alcohol and anxiolytic

83 We found that nociceptin moderately decreased IPSC amplitudes, acting

84 lanocortin (POMC) and pro-orphanin FQ (pOFQ)/nociceptin (N), in the brain.

85 bound conformation of the endogenous ligand, nociceptin (NC), several conformationally constrained an

86 Nociceptin (NCC, also known as FQ (N/OFQ)) is the 17-ami

87 drenaline (NA), and neuropeptides, including nociceptin (Noc), influence the excit ability of SG neur

88 f the mu (MOP), delta (DOP), kappa (KOP) and nociceptin (NOP) opioid peptide receptor genes have been

89 The nociceptin (NOP) receptor is a G-protein-coupled recepto

90 for the orphan opioid receptor, orphanin FQ/nociceptin (OFQ), has recently been characterized.

91 and the orphan receptor agonist orphanin FQ/nociceptin (OFQ).

92 The opioid peptide, Orphanin FQ/nociceptin (OFQ/N(1-17))(,) its active fragments, and a

93 Orphanin FQ/nociceptin (OFQ/N) and its receptor (ORL-1) have been pr

94 Orphanin FQ/nociceptin (OFQ/N) and its receptor share substantial st

95 n studies revealed expression of orphanin-FQ/nociceptin (OFQ/N) receptor (NOR) mRNA in the SCN, where

96 Orphanin FQ/nociceptin (OFQ/N) suppresses the activity of the dopami

97 Orphanin/nociceptin (OFQ/N), a 17-amino-acid peptide, is an endog

98 The heptadecapeptide, orphanin FQ/nociceptin (OFQ/N), binds with high affinity to the ORL-

99 Orphanin FQ/nociceptin (OFQ/N), the endogenous ligand for the ORL-1/

100 The heptadecapeptide orphanin FQ or nociceptin (OFQ/N), the endogenous ligand for the orphan

101 bles dynorphin, was named 'orphanin FQ' and 'nociceptin' (OFQ/N1-17).The OFQ/N1-17 receptor is expres

102 Nociceptin/OFQ (N/OFQ) is a 17 amino acid peptide that i

103 We tested the effect of nociceptin on acid-induced cough in conscious guinea pig

104 sults indicate that the inhibitory effect of nociceptin on acid-induced cough may result from a direc

105 preparation, we investigated the effects of nociceptin on glutamatergic transmission and its interac

106 Here, we investigated the effect of nociceptin on IPSCs in CeA neurons and its interaction w

107 upled with moderate affinity and efficacy at nociceptin opioid peptide (NOP) receptors will have util

108 n the two decades since the discovery of the nociceptin opioid receptor (NOP) and its ligand, nocicep

109 and identification of biased ligands at the nociceptin opioid receptor.

110 Nociceptin opposes CRF effects on CeA GABAergic transmis

111 Despite this, the spinal administration of nociceptin or agonists that activate ORL1 (opioid-like o

112 delta, and kappa opioid agonists as well as nociceptin or orphanin FQ (N/OFQ) peptide, an endogenous

113 rmine the role of the newly described opioid nociceptin orphanin FQ (NOC/oFQ) in such impaired dilati

114 e contribution of the newly described opioid nociceptin orphanin FQ (NOC/oFQ) to hypoxic-ischemic imp

115 Nociceptin (Orphanin FQ) is a newly discovered endogenou

116 The effects of nociceptin (orphanin FQ) on medial vestibular nucleus (M

117 High affinity and saturable nociceptin (orphanin FQ) receptors were detected and cha

118 nd brain antistress systems (neuropeptide Y, nociceptin [orphanin FQ]) in drug dependence, with empha

119 ole of carboxyl-terminal regulation of NOPR (nociceptin, orphanin FQ receptor) signaling and function

120 In contrast, enkephalins (100-1000 nmol) and nociceptin-orphanin FQ (3-30 nmol) only inhibit pain wit

121 f ligands with mixed mu opioid peptide (MOP)/nociceptin-orphanin FQ peptide (NOP) receptor agonist ac

122 peptide systems have attracted interest, the nociceptin/orphanin FQ (N/OFQ) and orexin/hypocretin (Or

123 Although nociceptin/orphanin FQ (N/OFQ) influences dopamine (DA)

124 Nociceptin/Orphanin FQ (N/OFQ) is an endogenous ligand o

125 Nociceptin/orphanin FQ (N/OFQ) is an endogenous ligand o

126 Nociceptin/orphanin FQ (N/OFQ) is the endogenous ligand

127 The nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor is

128 p between neuropsychiatric disorders and the nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor.

129 ing of natively and heterologously expressed nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptors w

130 logical criteria in the 1970s and 1980s, the nociceptin/orphanin FQ (N/OFQ) peptide receptor (NOP, al

131 implicated the hypocretin/orexin (Hcrt) and nociceptin/orphanin FQ (N/OFQ) peptidergic systems in th

132 he primary mediator of stress responses, and nociceptin/orphanin FQ (N/OFQ) plays an important role i

133 this issue, we evaluated whether blockade of nociceptin/orphanin FQ (N/OFQ) tone potentiated the anti

134 cistatin, a product of the same precursor as nociceptin/orphanin FQ (N/OFQ), has been shown to antago

135 udy we investigated whether the neuropeptide nociceptin/orphanin FQ (N/OFQ), previously implicated in

136 Nociceptin/orphanin FQ (N/OFQ), the endogenous agonist f

137 Since its discovery, the nociceptin/orphanin FQ (N/OFQ)-NOP receptor system has b

138 sible biologically active conformation(s) of nociceptin/orphanin FQ (N/OFQ).

139 The opiate-like peptide nociceptin/orphanin FQ (Noc) and its receptor [opiate re

140 tery dilation to the newly described opioid, nociceptin/orphanin FQ (NOC/oFQ) following hypoxia/ische

141 Nociceptin/orphanin FQ (NOC/oFQ) is a recently discovere

142 tery dilation to the newly described opioid, nociceptin/orphanin FQ (NOC/oFQ), following hypoxia/isch

143 elevates the CSF concentration of the opioid nociceptin/orphanin FQ (NOC/oFQ), which contributes to i

144 Corticotropin-releasing factor (CRF) and nociceptin/orphanin FQ (nociceptin) regulate ethanol int

145 ates several addiction-related processes and nociceptin/orphanin FQ (nociceptin) regulates ethanol in

146 Opioid peptides and nociceptin/orphanin FQ (nociceptin) within the CeA are i

147 The nociceptin/orphanin FQ (NOP) receptor, the fourth member

148 Nociceptin/orphanin FQ (NOP/OFQ) is the endogenous ligan

149 Nociceptin/orphanin FQ is a recently discovered neuropep

150 significant colocalization with MCH neurons: nociceptin/orphanin FQ opioid receptor (NOP), MCHR1, bot

151 Here we examine biased signaling at the nociceptin/orphanin FQ opioid receptor (NOPR), the most

152 n following activation of the adrenergic and nociceptin/orphanin FQ peptide (NOP) opioid receptors, r

153 Nociceptin/orphanin FQ peptide (NOP) receptor is a new c

154 e transmitter nociceptin, which binds to the nociceptin/orphanin FQ peptide (NOP) receptor, is a core

155 de ((11)C-NOP-1A), a new radioligand for the nociceptin/orphanin FQ peptide (NOP) receptor, with high

156 50 = 1.6 and 4.1 nM, respectively) at human nociceptin/orphanin FQ peptide (NOP) receptors.

157 lase (AC) by agonists to delta-opioid (DOR), nociceptin/orphanin FQ peptide (NOPr), alpha2-adrenergic

158 st in its activities at the kappa opioid and nociceptin/orphanin FQ peptide receptors.

159 affinity at the fourth opioid receptor, the nociceptin/orphanin FQ receptor (NOP).

160 pharmacodynamics, morphine metabolites, the nociceptin/orphanin FQ receptor system, acute opioid tol

161 ke receptor (ORL1) and its endogenous ligand nociceptin/orphanin FQ, which displayed anti-opioid prop

162 ceptin opioid receptor (NOP) and its ligand, nociceptin/orphaninFQ (N/OFQ), steady progress has been

163 tered intracerebroventricularly, orphanin FQ/nociceptin produces hyperalgesia and/or reverses opioid

164 The nociceptin receptor (Noci-R) is a G protein-coupled rece

165 Application of [Nphe1]Nociceptin(1-13)NH2, a nociceptin receptor (NOP) antagonist, revealed tonic inh

166 were discovered as a new structural class of nociceptin receptor (NOP) ligands.

167 l and anxiolytic properties and identify the nociceptin receptor as a useful therapeutic target for a

168 e searches, affording hits with demonstrated nociceptin receptor binding affinities.

169 ve been synthesized and shown to bind to the nociceptin receptor with high affinity.

170 , and kappa opioid receptors and the related nociceptin receptor, ORL1, each couple to Galphaqi5, Gal

171 the link comes from mutant mice lacking the nociceptin receptor, which show improved learning and me

172 the opioid receptors and antagonists at the nociceptin receptor.

173 H2 (7) was linked to peptide ligands for the nociceptin receptor.

174 tor (kappa-OR), but it is ineffective at the nociceptin receptor.

175 receptors (MORs and DORs, respectively) and nociceptin receptors (NOPRs).

176 s support a role for medications that target nociceptin receptors in the treatment of alcohol use dis

177 ing factor (CRF) and nociceptin/orphanin FQ (nociceptin) regulate ethanol intake and anxiety-like beh

178 elated processes and nociceptin/orphanin FQ (nociceptin) regulates ethanol intake and anxiety-like be

179 Nociceptin selectively inhibited only the sustained comp

180 Consequently, loss of somatostatin and nociceptin signaling leads to severe reduction of lens f

181 Nociceptin-stimulated PMN infiltration was inhibited by

182 ntake and relapse, including the urocortins, nociceptin, substance P, and neuropeptide S.

183 olds are elevated by approximately 70%, i.t. nociceptin substantially attenuates jump thresholds in a

184 e studies implicate a potential role for the nociceptin system in regulating glutamatergic transmissi

185 of spinal nociceptive pathways that utilize nociceptin to the etiology of extraordinary painful preg

186 s by forskolin treatment up-regulates prepro-nociceptin transcription.

187 does not necessarily rule out alterations in nociceptin transmission in alcohol dependence.

188 The effect of nociceptin was antagonized by naloxone benzoylhydrazone

189 U69593) was unchanged, whereas the effect of nociceptin was increased.

190 onstant was significant even at low doses of nociceptin which did not cause other observable behaviou

191 id receptor-like receptor ORL(1) (orphaninFQ/nociceptin) which may mediate nociceptive or antinocicep

192 The neuropeptide transmitter nociceptin, which binds to the nociceptin/orphanin FQ pe

193 that both these cell types are responsive to nociceptin, which induced membrane hyperpolarisation and

194 ioid receptors) did not block the effects of nociceptin, while it did block the effects of endomorphi

195 pression of the peptidergic neurotransmitter nociceptin, while minimally affecting the expression of

196 Opioid peptides and nociceptin/orphanin FQ (nociceptin) within the CeA are implicated also in regula